title: Effects of increasing doses of 1 alpha-hydroxyvitamin D2 on calcium homeostasis in postmenopausal osteopenic women.
abstract: This study is the first reported administration of 1 alpha-hydroxyvitamin D2 (1 alpha-OHD2) to human subjects. A total of 15 postmenopausal osteopenic women were given increasing oral doses of 1 alpha-OHD2, beginning with a low dose of 0.5 microgram/day. In 15 subjects, the doses were raised at weekly intervals to 1.0, 2.0, 4.0, and 5.0 micrograms/day, and in 5 of these subjects, the dose was further increased to 8.0 or 10.0 micrograms/day. Mean urine calcium +/- SEM showed a dose-related increase from 134 +/- 17 mg/24 h on 0.5 microgram/day to 198 +/- 21 mg/24 h on 4.0 micrograms/day (p < 0.05) and to 241 +/- 35 mg/24 h on 5.0 micrograms/day (p < 0.05). No subjects had hypercalciuria (> 350 mg/24 h, the upper limit of the laboratory normal range) at doses less than 5.0 micrograms/day; 5 subjects had hypercalciuria at or above 5.0 micrograms/day (3 at 5.0 micrograms/day, 1 at 8.0 micrograms/day, and 1 at 10.0 micrograms/day). Mean serum calcium increased slightly on the 4.0 micrograms dose only (p < 0.05) but remained well within the normal range. Mean creatinine clearance and BUN, used as measures of renal function, showed no significant changes. Routine blood and urine assays also showed no significant changes.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Bone Metabolism Unit, Creighton University School of Medicine, Omaha, Nebraska.
authors.forename: J C
authors.initials: JC
authors.lastname: Gallagher
authors.forename: C W
authors.initials: CW
authors.lastname: Bishop
authors.forename: J C
authors.initials: JC
authors.lastname: Knutson
authors.forename: R B
authors.initials: RB
authors.lastname: Mazess
authors.forename: H F
authors.initials: HF
authors.lastname: DeLuca
mesh_terms: D000284:Administration, Oral; D000368:Aged; D015519:Bone Density / Q000187:drug effects; D001851:Bone Diseases, Metabolic / Q000188:drug therapy*; D002118:Calcium / Q000097:blood* / Q000652:urine; D004305:Dose-Response Relationship, Drug; D004872:Ergocalciferols / Q000008:administration & dosage* / Q000494:pharmacology / Q000627:therapeutic use; D005260:Female; D006706:Homeostasis / Q000187:drug effects; D006801:Humans; D008875:Middle Aged; D015675:Osteocalcin / Q000097:blood*; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy
chemical_list: D004872:Ergocalciferols; D015675:Osteocalcin; C042533:1 alpha-hydroxyergocalciferol; D002118:Calcium